Metabolic Capacity of Israeli Populations

This study has been terminated.
Information provided by:
Hadassah Medical Organization Identifier:
First received: September 11, 2005
Last updated: October 28, 2008
Last verified: October 2008

The ability to metabolize drugs varies greatly among individuals. Major fraction of this variability lies in genetic polymorphisms of genes encoding for enzymes responsible for both phase I and phase II reactions.

The purpose of this study ws to evaluate the phenotypic activity and the frequency of genetic polymorphisms in different phase II and phase I enzymes among various populations residing in Israel.

Condition Intervention
Healthy Volunteers
Drug: Debrisoquine
Drug: Mephenytoin
Drug: Dapsone
Drug: Caffeine

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Official Title: Phenotypic and Genotypic Evaluation of Cytochrome P450 Isoforms in Populations of Different Ethnic Composition

Further study details as provided by Hadassah Medical Organization:

Primary Outcome Measures:
  • Phenotypic measurements of various P450 and non-P450 enzymes involved in drug metabolism.
  • Frequency of genetic polymorphisms in these enzymes among different Israeli populations.

Estimated Enrollment: 1200
Study Start Date: July 1995

Ages Eligible for Study:   20 Years to 50 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Age range 20-50
  • Absence of significant disease state

Exclusion Criteria:

  • The presence of significant disease states
  • The regular use of drugs (including birth control pills)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00162383

Hadassah Medical Organization
Jerusalem, Israel
Sponsors and Collaborators
Hadassah Medical Organization
Principal Investigator: Yoseph Caraco, MD Hadassah Medical Organization
  More Information

No publications provided Identifier: NCT00162383     History of Changes
Other Study ID Numbers: yc19551-HMO-CTIL 
Study First Received: September 11, 2005
Last Updated: October 28, 2008
Health Authority: Israel: Israeli Health Ministry Pharmaceutical Administration processed this record on February 07, 2016